Clinical trial

MC2-11 PAD™ Cream – Atopic dermatitis

About Atopic Dermatitis
Atopic dermatitis is a chronic rash characterized by inflammation and itching. An estimated 30-40 million people in the US and EU suffer from this condition, including between 8 and 18 % of infants and children.

Aim of MC2-11
Tacrolimus is the best non-steroidal topical therapy for moderate to severe atopic dermatitis with clinical trial efficacy data significantly superior to pimecrolimus (Elidel Cream) and crisaborole ointment. However, the current marketed formulation of tacrolimus (Protopic) is a greasy ointment that patients do not like to use, resulting in non-compliance and poor real-life efficacy.

Using PAD™ Technology and related know-how we have uniquely developed a stabile cream formulation of tacrolimus MC2-11 Cream designed to deliver tacrolimus into the skin in quantities at least corresponding to Protopic 0.1%. Our aim is to develop two concentrations of MC2-11 Cream into new non-steroidal drugs (NDA/MAA) for adults and children with a best-in-class real-life efficacy profile. MC2-11 Cream is moisturizing, convenient-to-use and it quickly absorbs into the skin allowing patients to move on in daily routines. A solution intended to significantly improve daily quality of life of patients and provide a cost effective treatment.

Clinical Stage
Pre-clinical – in preparation for phase II in 2017